kvejdani

4 ms·

1.
by kvejdani 9y ago
There is only so much that can go into a short essay about the story and aspirations of a disruptive startup company. This story was not meant to be a scientific publication. We are working with FDA and expecting to receive approval within
2.
by kvejdani 9y ago
Darmiyan's product is NOT a probabilistic risk assessment test, and is NOT intended for use by the general public. There are already too many tests in the market for risk assessment, which are just probability numbers. Darmiyan's
3.
by kvejdani 9y ago
There's currently no method to screen brain tissue health at the microscopic level. Darmiyan aims to provide that tool.
4.
by kvejdani 9y ago
We understand the level of rightful skepticism from the community given all previous failed big claims by others. There are many tests to tell you the risk of developing dementia, which is merely a "probability" number. Darmiyan&#
5.
by kvejdani 9y ago
There is currently no other early-detection technology to show (and measure) microstructural abnormality in the brain before symptoms of cognitive decline. State of art Amyloid PET is extremely non-specific, with a positive predictive value
6.
by kvejdani 9y ago
Somewhat correct. If you test the software with a 1000 MRI scans from people with known diagnoses, the software will diagnose ~900 of them correctly. Roughly 97% sensitivity (3% false negative) and 85% specificity (15% false positive). Fals
7.
by kvejdani 9y ago
Great question. Web upload tool is in development, will launch in a few months. Stay tuned!
8.
Launch HN: Darmiyan (YC S17) – Early Detection of Alzheimer's Disease
69 points by kvejdani 9y ago|70 comments
9.
Darmiyan Inc. is hiring a strong full-stack web developer(darmiyan.com)
1 points by kvejdani 9y ago